Literature DB >> 27075042

Waning population immunity prior to a large Q fever epidemic in the south of The Netherlands.

D A H Brandwagt1, T Herremans1, P M Schneeberger2, V H Hackert3, C J P A Hoebe3, J Paget4, W VAN DER Hoek1.   

Abstract

Historical survey data suggest that the seroprevalence of antibodies against Coxiella burnetii in the general population of The Netherlands decreased from more than 40% in 1983 to 2·4% in 2007, just before the start of the large 2007-2010 Q fever epidemic. To assess whether the sharp decline in seroprevalence was real, we performed a cross-sectional study using historical samples. We tested samples using a contemporary commercial indirect immunofluorescence assay. In plasma samples from the south of The Netherlands from 1987, we found an age- and sex-standardized seroprevalence of 14·4% (95% confidence interval 11·2-18·3). This was significantly lower than a 1983 estimate from the same area (62·5%), but significantly higher than 2008 (1·0%) and 2010 (2·3%) estimates from the same area. The study suggests that there was a steady and sharp decline in Q fever seroprevalence in the south of The Netherlands from 1987 to 2008. We assume that seroprevalence has decreased in other parts of The Netherlands as well and seroprevalence surveys in other European countries have shown a similar declining trend. Waning population immunity in The Netherlands may have contributed to the scale of the 2007-2010 Q fever epidemic. For a better understanding of the infection dynamics of Q fever, we advocate an international comparative study of the seroprevalence of C. burnetii.

Entities:  

Keywords:  Coxiella; Q fever; epidemiology; infectious disease epidemiology; zoonoses

Mesh:

Year:  2016        PMID: 27075042      PMCID: PMC9150411          DOI: 10.1017/S0950268816000741

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  33 in total

Review 1.  The Q fever epidemic in The Netherlands: history, onset, response and reflection.

Authors:  H I J Roest; J J H C Tilburg; W van der Hoek; P Vellema; F G van Zijderveld; C H W Klaassen; D Raoult
Journal:  Epidemiol Infect       Date:  2010-10-05       Impact factor: 2.451

2.  Genotyping reveals the presence of a predominant genotype of Coxiella burnetii in consumer milk products.

Authors:  Jeroen J H C Tilburg; Hendrik Jan I J Roest; Marrigje H Nabuurs-Franssen; Alphons M Horrevorts; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-04-11       Impact factor: 5.948

3.  The 2007–2010 Q fever epidemic in The Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming.

Authors:  Frederika Dijkstra; Wim van der Hoek; Nancy Wijers; Barbara Schimmer; Ariene Rietveld; Clementine J Wijkmans; Piet Vellema; Peter M Schneeberger
Journal:  FEMS Immunol Med Microbiol       Date:  2012-02

4.  Prevalence of Q fever in a rural practice.

Authors:  T R Davies; Y Edwards; A Morgan; E O Caul
Journal:  J Public Health Med       Date:  1997-09

5.  High seroprevalence of Coxiella burnetii infection in Eastern Cantabria (Spain).

Authors:  F Pascual-Velasco; M Montes; J M Marimón; G Cilla
Journal:  Int J Epidemiol       Date:  1998-02       Impact factor: 7.196

6.  [Seroepidemiological investigations on the prevalence of rickettsial antibodies in man in the Federal Republic of Germany (author's transl)].

Authors:  H D Schmatz; S Schmatz; H Krauss; A Weber; H Brunner
Journal:  Immun Infekt       Date:  1977-08

7.  Q fever in the Netherlands: a sero-epidemiological survey among human population groups from 1968 to 1983.

Authors:  J H Richardus; A Donkers; A M Dumas; G J Schaap; J P Akkermans; J Huisman; H A Valkenburg
Journal:  Epidemiol Infect       Date:  1987-04       Impact factor: 2.451

8.  Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases.

Authors:  H Tissot Dupont; D Raoult; P Brouqui; F Janbon; D Peyramond; P J Weiller; C Chicheportiche; M Nezri; R Poirier
Journal:  Am J Med       Date:  1992-10       Impact factor: 4.965

9.  Antibodies against Coxiella burnetii and pregnancy outcome during the 2007-2008 Q fever outbreaks in The Netherlands.

Authors:  Wim van der Hoek; Jamie C E Meekelenkamp; Alexander C A P Leenders; Nancy Wijers; Daan W Notermans; Chantal W P M Hukkelhoven
Journal:  BMC Infect Dis       Date:  2011-02-11       Impact factor: 3.090

10.  Molecular epidemiology of Coxiella burnetii from ruminants in Q fever outbreak, the Netherlands.

Authors:  Hendrik I J Roest; Robin C Ruuls; Jeroen J H C Tilburg; Marrigje H Nabuurs-Franssen; Corne H W Klaassen; Piet Vellema; René van den Brom; Daan Dercksen; Willem Wouda; Marcel A H Spierenburg; Arco N van der Spek; Rob Buijs; Albert G de Boer; Peter Th J Willemsen; Fred G van Zijderveld
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

View more
  4 in total

Review 1.  Sex and bacterial infectious diseases.

Authors:  J-L Mege; F Bretelle; M Leone
Journal:  New Microbes New Infect       Date:  2018-06-06

2.  Sero-prevalence of brucellosis, Q-fever and Rift Valley fever in humans and livestock in Somali Region, Ethiopia.

Authors:  Mohammed Ibrahim; Esther Schelling; Jakob Zinsstag; Jan Hattendorf; Emawayish Andargie; Rea Tschopp
Journal:  PLoS Negl Trop Dis       Date:  2021-01-25

3.  Remarkable spatial variation in the seroprevalence of Coxiella burnetii after a large Q fever epidemic.

Authors:  Roan Pijnacker; Johan Reimerink; Lidwien A M Smit; Arianne B van Gageldonk-Lafeber; Jan-Paul Zock; Floor Borlée; Joris Yzermans; Dick J J Heederik; Catharina B M Maassen; Wim van der Hoek
Journal:  BMC Infect Dis       Date:  2017-11-21       Impact factor: 3.090

4.  Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands.

Authors:  Pieter T de Boer; Marit M A de Lange; Cornelia C H Wielders; Frederika Dijkstra; Sonja E van Roeden; Chantal P Bleeker-Rovers; Jan Jelrik Oosterheert; Peter M Schneeberger; Wim van der Hoek
Journal:  Emerg Infect Dis       Date:  2020-02       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.